

Dr. Javier Cortes Castan is a distinguished oncologist specializing in breast malignancy and gynecological tumors. With over 20 years of experience, he has established himself as a leading figure in the field, renowned for his expertise and dedication to advancing cancer research. Dr. Cortes Castan's primary focus lies in pioneering research aimed at revolutionizing the treatment of breast cancer, with a vision of significantly improving outcomes for patients in the near future. Educated at the Autonomous University and the University of Navarra, Dr. Cortes Castan underwent specialized training in oncology, during which he actively contributed to the Sector of Cancer. Currently, he serves as a key figure in the Medical Oncology sector at the Vall d'Hebron Hospital in Barcelona and leads the breast malignancy project at the IOB Cancer center. Additionally, he holds the position of Chief of the Breast Oncology unit at the prestigious Ruber International Hospital in Madrid. Dr. Cortes Castan's remarkable contributions to oncology include leading roles in the development of cutting-edge medications and significant involvement in numerous cancer research projects worldwide. He is a member of various international Cancer Societies and the Scientific society ESMO, demonstrating his commitment to advancing the field of oncology through collaboration and innovation.
Dr. Javier Cortes Castan is a highly respected medical oncologist whose career is defined by a strong integration of clinical excellence, scientific leadership, and translational research. Specializing in breast malignancy and gynecological tumors, he has played a pivotal role in shaping modern breast cancer treatment through his involvement in landmark research projects and drug development programs. His work at Vall d’Hebron Hospital, IOB Cancer Center, and Ruber International Hospital reflects a commitment to evidence-based oncology and innovation-driven care. Known for bridging research with clinical practice, Dr. Cortes Castan continues to influence international oncology standards through collaborative research, clinical trials, and leadership within major scientific societies.